Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2015-12-23
|
selexipag |
pulmonary arterial hypertension (PAH) |
3 |
Actelion (Switzerland) |
Rare diseases - Cardiovascular diseases |
2015-12-22
|
AMG 176 |
relapsed or refractory multiple myeloma |
1 |
Amgen (USA - CA) |
Cancer - Oncology |
2015-12-22
|
MM-121 (seribantumab) |
non-small cell lung cancer |
2 |
Merrimack Pharmaceuticals (USA - MA) |
Cancer - Oncology |
2015-12-22
|
avelumab (MSB0010718C) |
urothelial cancer |
3 |
Pfizer (USA - NY) Merck KGaA (Germany) |
Cancer - Oncology |
2015-12-22
|
avelumab (MSB0010718C) |
ovarian cancer |
3 |
Pfizer (USA - NY) Merck KGaA (Germany) |
Cancer - Oncology |
2015-12-21
|
Samcyprone™ (diphenylcyclopropenone gel) |
cutaneous warts caused by human papillomaviruses |
2 |
RXi Pharmaceuticals (USA - MA) |
Dermatological diseases - Infectious diseases |
2015-12-21
|
C-Cure®( C3BS-CQR-1) |
heart failure |
3 |
Celyad (Belgium) |
Cardiovascular diseases |
2015-12-21
|
Adynovate® - BAX 855 |
hemophilia A |
|
Baxalta (USA - IL) |
Rare diseases - Genetic diseases - Hematological diseases |
2015-12-21
|
JNJ-54257099/AL-704 |
chronic hepatitits C |
1 |
Alios Biopharma, a J&J company (USA - NJ) Janssen Pharmaceutica, a J&J company (USA - NJ) |
Infectious diseases |
2015-12-21
|
AGS-16C3F |
metastatic renal cell carcinoma (mRCC) |
2 |
Astellas Pharma (Japan) Agensys (USA - CA) |
Cancer - Oncology |
2015-12-21
|
JNJ-64041809/ADU-741 |
metastatic castration-resistant prostate cancer (mCRPC) |
1 |
Janssen Research & Development, a J&J company (USA - NJ) |
Cancer - Oncology |
2015-12-21
|
CCP-07 |
cough |
|
Vernalis (UK) |
Respiratory diseases |
2015-12-19
|
Keytruda® (pembrolizumab) |
patients with non-small cell lung cancer (NSCLC) who have experienced disease progression after platinum-containing systemic therapy |
2-3 |
Merck&Co (USA - NJ) |
Cancer - Oncology |
2015-12-18
|
durvalumab (MEDI4736) |
locally advanced or metastatic programmed death ligand-1 (PD-L1) positive non-small cell lung cancer (NSCLC) that lacks epidermal growth factor receptor (EGFR) or ALK alterations |
2 |
AstraZeneca (UK) |
Cancer - Oncology |
2015-12-18
|
AG-120 - isocitrate dehydrogenase 1 (IDH1)-mutant inhibitor, AG-221 (enasidenib) |
acute myeloid leukemia (AML) |
1b |
Celgene (USA - NJ) Agios Pharmaceuticals (USA -MA) |
Cancer - Oncology |
2015-12-16
|
enadenotucirev and pembrolizumab |
solid tumors including metastatic colorectal cancer |
1 |
PsiOxus Therapeutics (UK) |
Cancer - Oncology |
2015-12-16
|
ALKS 8700 (monomethyl fumarate) |
multiple sclerosis |
3 |
Alkermes (Ireland) |
Autoimmune diseases - Neurodegenerative diseases |
2015-12-16
|
Bronchitol® (mannitol) |
cystic fibrosis |
2 |
Pharmaxis (Australia) |
Rare diseases - Genetic diseases |
2015-12-15
|
algenpantucel-L |
pancreatic cancer |
3 |
NewLink Genetics (USA - IO) |
Cancer - Oncology |
2015-12-15
|
Imlygic® (talimogene laherparepvec) |
advanced non CNS tumors |
1 |
Amgen (USA - CA) |
Cancer - Oncology |